NASDAQ : SPTX
Seaport Therapeutics, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 21.1 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 1.13B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 1.07B |
| Enterprise Value | 802.85M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 2, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 53.53M |
| Shares Outstanding | 53.53M |
| Shares Change (YoY) | +1,101.91% |
| Shares Change (QoQ) | +51.92% |
| Owned by Insiders (%) | 4.58% |
| Owned by Institutions (%) | 41.19% |
| Float | 18.43M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 2.48 |
| P/TBV Ratio | 2.46 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 18.00 |
| Quick Ratio | 17.75 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | -33.78% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$2.39M |
| Employee Count | 58 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | 1.41M |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 21.07 |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 50.77 |
| Average Volume (20 Days) | 226,090 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 3.72M |
| Short Previous Month | 3.65M |
| Short % of Shares Out | 6.95% |
| Short % of Float | 20.17% |
| Short Ratio (days to cover) | 12.17 |
Incomestatement
| Measure | Value |
|---|
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -149.00M |
| Pretax Income | -137.13M |
| Net Income | -138.54M |
| EBITDA | -148.87M |
| EBIT | -149.00M |
| Earnings Per Share (EPS) | -$4.82 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 273.31M |
| Total Debt | 5.02M |
| Net Cash | 268.29M |
| Net Cash Per Share | $5.01 |
| Equity (Book Value) | 422.60M |
| Book Value Per Share | 7.89 |
| Working Capital | 266.50M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -88.73M |
| Capital Expenditures | -33,000 |
| Depreciation & Amortization | 128,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -88.76M |
| FCF Per Share | -$1.66 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -1,101.91% |
| Shareholder Yield | -1,101.91% |
| Earnings Yield | -24.10% |
| FCF Yield | -8.52% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $37.00 |
| Price Target Difference | 84.91% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 9 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |